Drug updated on 12/11/2024
| Dosage Form | Injection (intravenous; 300 MBq/mL to 3,700 MBq/mL [8.1 mCi/mL to 100 mCi/mL] of flortaucipir F 18 in a multiple-dose vial) |
| Drug Class | Radioactive diagnostic agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimers disease (AD).
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- Higher neuroticism was found to be associated with increased tau pathology in the entorhinal cortex, with a correlation coefficient of r=0.15 (p < .001), according to a meta-analysis of 8 studies. This association was stronger in cognitively normal individuals.
- Lower conscientiousness was linked to greater tau pathology, with a correlation coefficient of r=-0.14 (p < .001). This relationship was also more pronounced in cognitively normal individuals compared to those with neuropsychiatric symptoms.
- An empirical assessment of tau positron emission tomography (PET) cut-points revealed that the cut-point derived from 2 standard deviations above a comparison group in the temporal meta-region of interest (ROI) or entorhinal cortex best differentiated tau-positive and tau-negative groups based on cerebrospinal fluid phosphorylated tau levels, Mini-Mental State Examination scores, and delayed memory performance.
- There is no safety information available in the reviewed studies.
- The studies included cognitively normal participants and heterogeneous samples (possibly with neuropsychiatric symptoms), with stronger associations between neuroticism, conscientiousness, and tau pathology observed in cognitively normal individuals; older adults were specifically assessed in the tau PET cut-point study.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tauvid (flortaucipir F 18) Prescribing Information. | 2024 | Avid Radiopharmaceuticals, Philadelphia, PA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Personality Associations With Amyloid and Tau: Results From the Baltimore Longitudinal Study of Aging and Meta-analysis | 2022 | Biological Psychiatry |
| What’s the cut-point?: a systematic investigation of tau PET thresholding methods | Alzheimer's Research & Therapy |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease | 2022 | European Journal of Nuclear Medicine and Molecular Imaging |